P47 suppresses metastasis of HER2-positive breast cancer
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
List view / Grid view
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Treatment with Palbociclib and a compound targeting CAD increased survival to 100 percent for selected lymphoma cell lines.
Researchers have generated a SASP atlas of human colon fibroblasts and assessed the resulting transcriptome.
Researchers elucidate the significant role of CDX2 in regulating stemness and differentiation, particularly in the proximal colon’s epithelial cells. This research encourages new combinations of existing drugs, that inhibit both the BRAF and KRAS genes, to be explored.
Researchers have discovered that higher expression of gigaxonin suppresses aggressive growth of human head and neck cancer cells.
Researchers have identified that AF1q is highly expressed in neuroblastoma, and could be used to destabilise N-Myc.
In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.
A combination therapy of vincristine, irinotecan and panobinostat, tested in high-risk, relapsed or refractory HB spheroids, decreased tumour marker levels.
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.